Oxford Immunotec Global PLC (OXFD) Receives $19.75 Consensus PT from Analysts

Oxford Immunotec Global PLC (NASDAQ:OXFD) has been given a consensus rating of “Hold” by the seven research firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $19.75.

A number of analysts have recently weighed in on OXFD shares. Piper Jaffray Companies restated a “buy” rating and issued a $26.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Cowen and Company restated a “buy” rating and issued a $22.00 price objective on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. BTIG Research started coverage on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, ValuEngine cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded up $0.17 during trading on Friday, hitting $13.11. 144,100 shares of the stock were exchanged, compared to its average volume of 105,833. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global PLC has a twelve month low of $12.19 and a twelve month high of $19.51.

WARNING: This piece was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.thestockobserver.com/2017/11/14/oxford-immunotec-global-plc-oxfd-receives-19-75-consensus-pt-from-analysts.html.

In related news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the transaction, the director now directly owns 17,778 shares in the company, valued at approximately $237,336.30. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total transaction of $922,900.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,000 shares of company stock valued at $1,010,410. Corporate insiders own 8.11% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. American International Group Inc. raised its stake in Oxford Immunotec Global PLC by 7.1% during the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after purchasing an additional 904 shares during the last quarter. Parkwood LLC raised its stake in Oxford Immunotec Global PLC by 12.9% during the 2nd quarter. Parkwood LLC now owns 12,799 shares of the company’s stock valued at $215,000 after purchasing an additional 1,465 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Oxford Immunotec Global PLC by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after purchasing an additional 1,500 shares during the last quarter. Voya Investment Management LLC raised its stake in Oxford Immunotec Global PLC by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after purchasing an additional 1,845 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Oxford Immunotec Global PLC by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after purchasing an additional 2,053 shares during the last quarter. Hedge funds and other institutional investors own 78.79% of the company’s stock.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply